LynxDx
LynxDx is a privately held molecular diagnostics company that commercializes MyProstateScore 2.0 (MPS2), a urine-based 18-gene prostate cancer risk assessment test, serving urologists and primary-care providers across the United States.
- Company typePrivate
- Founded2015
- HeadquartersAnn Arbor, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What LynxDx does
Lynx Dx Inc. is a privately held molecular diagnostics company founded in 2015 and headquartered in Ann Arbor, Michigan. It commercializes urine-based genomic tests that help urologists and primary-care physicians risk-stratify men for clinically significant prostate cancer, reducing reliance on invasive biopsies and PSA-only decision-making. Its flagship product, MyProstateScore 2.0 (MPS2), analyzes 18 unique gene transcripts — including the T2:ERG gene fusion licensed exclusively from the University of Michigan — and can be configured as a biomarker-only test or inclusive of optional clinical risk factors (age, race, family history). Sample collection is non-DRE and does not require temperature-controlled shipping, enabling both in-office and at-home workflows.
The company's product family now spans three configurations: the core MPS2 test (for biopsy-naïve and prior-negative-biopsy patients), an at-home, non-DRE collection kit launched commercially in February 2025, and MPS2-AS (Active Surveillance), planned for launch in May 2026 to guide biopsy decisions in men with low-risk disease on surveillance. The business operates a fee-for-service laboratory model — physicians order tests through the provider portal (provider.mps2.com) or client services, samples are processed at the company's CAP-accredited, CLIA-certified, ISO 15189-accredited laboratory, and results are returned within 5–7 business days. Medicare coverage under CPT PLA 0403U took effect September 11, 2024, substantially expanding the addressable patient pool, while the LynxDx CARES program and an interest-free 6-month payment plan support uninsured or underinsured patients.
LynxDx sells primarily through physician-ordered channels, supported by inside sales, the at-home collection channel, conference presence (AUA, WSAUA), peer-reviewed publications, and a CARES financial-assistance program for patient access. The company is led by founder Dr. Arul M. Chinnaiyan and President & CEO Steve Riggs, with an executive team spanning commercial (ex-Myriad Genetics, ex-CardioDx), medical, financial, and technology functions. It reports 51–100 employees and operates exclusively in the United States.
LynxDx firmographics
Firmographics- Name
- LynxDx
- Legal name
- Lynx Dx Inc.
- Website
- https://lynxdx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- LynxDx is a privately held molecular diagnostics company that commercializes MyProstateScore 2.0 (MPS2), a urine-based 18-gene prostate cancer risk assessment test, serving urologists and primary-care providers across the United States.
- Ownership category
- akta.pro rank
LynxDx industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where LynxDx is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LynxDx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Laboratory Diagnostic Testing Services: One-time laboratory test revenue from MyProstateScore 2.0 (MPS2) urine biomarker test. Physicians order tests for patients, samples are collected (in-office or at-home) and shipped to LynxDx laboratory for analysis. Results reported to ordering physician within 5-7 business days. Revenue recognized upon test completion and report delivery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Medicare-covered diagnostic testing |
| One time/ perpetual license | Pay-as-you-go | Commercial insurance patients |
| Other | Pay-as-you-go | LynxDx CARES financial assistance program |
| Other | Monthly | Payment plan option |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
LynxDx product offering
Product offeringCore offering
LynxDx offers MyProstateScore 2.0 (MPS2), a urine-based genomic molecular diagnostic test that analyzes 18 unique gene transcripts—including the proprietary T2:ERG gene fusion biomarker—to predict the presence of clinically significant prostate cancer. The test is ordered by physicians (primarily urologists), with samples collected either in-office or at-home without a digital rectal exam (DRE), then shipped to the company's CAP/CLIA/ISO 15189-accredited laboratory in Ann Arbor, Michigan for analysis. Results are reported back to the ordering physician within 5–7 business days, with variants available for active surveillance patients (MPS2-AS) and at-home non-DRE collection.
Product overview
LynxDx offers MyProstateScore 2.0 (MPS2) as its core product, a urine-based prostate cancer risk assessment test that analyzes 18 unique gene transcripts to predict clinically significant prostate cancer. The flagship product can be configured as a biomarker-only test or with optional clinical risk factors, and is available for both biopsy-naïve patients and those with prior negative biopsies. The MPS2 At-Home Collection Kit provides a convenient add-on allowing patients to collect samples without a DRE from home, with no special shipping requirements. The company has also launched MPS2-AS (Active Surveillance variant) specifically for men on active surveillance to guide biopsy decisions.
Differentiator
Problem solved
Functional benefit
Brands
- MyProstateScore 2.0 (MPS2): Urine-based test for prostate cancer risk assessment analyzing 18 unique gene transcripts, designed for both biopsy-naïve patients and those with prior negative biopsies.
- MPS2-AS (MyProstateScore 2.0 – Active Surveillance)
- CARES Program
Products and services
- MyProstateScore 2.0 (MPS2)
Quantifiable outcome
- 97% sensitivity and 99% NPV for Grade Group 3 or higher upgrading in active surveillance patients
- +5 more outcomes
Companies that use LynxDx
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
LynxDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
LynxDx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of MichigancoreFounding partnership with University of Michigan's urology department. Technology developed at Michigan Center for Translational Pathology. LynxDx holds exclusive license from University of Michigan to commercialize T2:ERG gene fusion and MPS2 technology. Research collaboration continues with University of Michigan scientists.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
LynxDx competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Leading cancer screening diagnostics company (Cologuard, Oncotype DX) operating a high-volume CLIA lab with direct-to-patient and physician-channel distribution. Highly comparable business model to LynxDx in cancer molecular diagnostics, at a far larger scale, with established Medicare reimbursement infrastructure.
- Myriad Genetics: Established molecular diagnostics company with Prolaris (prostate cancer aggressiveness test) directly competing in the prostate cancer risk-stratification market. LynxDx's CCO Mark Willig is a former Myriad CCO, signaling direct operational familiarity and head-to-head competition in the same urology channel.
- Veracyte: Genomic diagnostics company focused on urologic and oncologic testing (Decipher Prostate, Afirma thyroid). Operates a urologist-targeted commercial channel with Medicare-covered molecular tests, making it a directly comparable peer in clinical evidence requirements, sales motion, and reimbursement dynamics.
- MDxHealth: Commercial-stage urologic oncology diagnostics company offering SelectMDx (a urine-based prostate cancer risk test) and ConfirmMDx. Directly comparable to LynxDx in target customer (urologists), product type (urine molecular biomarker test for prostate biopsy decisions), and reimbursement model (Medicare LCD-covered).
Broad incumbents
- OPKO Health (BioReference Laboratories): Diversified diagnostics and pharma company whose BioReference Laboratories subsidiary offers the 4Kscore prostate cancer test. Competes with LynxDx in urology-channel prostate diagnostics but operates at much larger scale as part of a broader clinical lab portfolio.
- Bio-Techne: Large life-sciences tools and diagnostics company offering ExoDx Prostate (EPI) — a urine exosome-based gene expression test for prostate cancer. Directly comparable as a competing molecular prostate diagnostic, though Bio-Techne operates at significantly larger scale with a broader life-sciences portfolio.
- Hologic: Major women's health-focused diagnostics and medical device company that has expanded into adjacent oncology screening markets. While not a direct prostate diagnostic competitor, it represents a comparable large-cap strategic acquirer profile and molecular diagnostics commercialization capability relevant to LynxDx's exit landscape.
- NeoGenomics: Specialized oncology reference laboratory offering a broad menu of molecular and anatomic pathology services including prostate cancer testing. Operates a similar hospital/urology-channel sales model with Medicare-reimbursed molecular tests, though at substantially larger scale and with a more diversified test menu.
Emerging players
- Nucleix: Israeli-based developer of urine-based epigenetic cancer diagnostics (Prostate EpiCheck for prostate cancer recurrence monitoring). Directly comparable in sample type (urine), technology (methylation-based molecular assay), and target use case (prostate cancer risk assessment/active surveillance), though currently more focused on the European market.
- Strata Oncology: Emerging precision oncology company offering molecular profiling and liquid-biopsy-based MRD testing. Comparable as a similarly-staged molecular diagnostics company navigating Medicare coverage and urology/oncology channel adoption, though currently focused on pan-cancer solid tumor profiling rather than prostate-specific risk assessment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LynxDx compliance and trust
Trust signalCompliance5 records
LynxDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
LynxDx leadership team
Management profileNumber of profiles
Profiles9 records
LynxDx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LynxDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LynxDx
What does LynxDx do?
LynxDx offers MyProstateScore 2.0 (MPS2), a urine-based genomic molecular diagnostic test that analyzes 18 unique gene transcripts—including the proprietary T2:ERG gene fusion biomarker—to predict the presence of clinically significant prostate cancer. The test is ordered by physicians (primarily urologists), with samples collected either in-office or at-home without a digital rectal exam (DRE), then shipped to the company's CAP/CLIA/ISO 15189-accredited laboratory in Ann Arbor, Michigan for analysis. Results are reported back to the ordering physician within 5–7 business days, with variants available for active surveillance patients (MPS2-AS) and at-home non-DRE collection.
Is LynxDx a public or private company?
LynxDx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was LynxDx founded?
LynxDx was founded in 2015. It employs 51 to 100 people.
Where is LynxDx based?
LynxDx is headquartered in Ann Arbor, United States, in the North America region.
How does LynxDx make money?
One revenue line is on record: laboratory Diagnostic Testing Services.
Who are LynxDx's main competitors?
Direct peers on record are Exact Sciences, Myriad Genetics, Veracyte and MDxHealth. Broad incumbents are OPKO Health (BioReference Laboratories), Bio-Techne, Hologic and NeoGenomics. Emerging players are Nucleix and Strata Oncology.
Does LynxDx have an API?
No public API is recorded for LynxDx.
What industry is LynxDx in?
LynxDx's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 62151 and its SIC code is 8071.